Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy

Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy

BackgroundPediatric acute myeloid leukemia (AML) therapy is associated with substantial short- and long-term treatment-related cardiotoxicity mainly due to high-dose anthracycline exposure. Early left ventricular systolic dysfunction (LVSD) compromises anthracycline delivery and is associated with i...

Full description

Bibliographic Details
Main Authors: Kasey J. Leger, Nora Robison, Hari K. Narayan, Amanda M. Smith, Tenaadam Tsega, Jade Chung, Amber Daniels, Zhen Chen, Virginia Englefield, Biniyam G. Demissei, Benedicte Lefebvre, Gemma Morrow, Ilona Dizon, Robert B. Gerbing, Reena Pabari, Kelly D. Getz, Richard Aplenc, Jessica A. Pollard, Eric J. Chow, W. H. Wilson Tang, William L. Border, Ritu Sachdeva, Todd A. Alonzo, E. Anders Kolb, Todd M. Cooper, Bonnie Ky
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
pediatric acute myeloid leukemia (AML)
liposomal anthracycline
CPX-351
dexrazoxane
cardiotoxicity
risk prediction
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1286241/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1286241/full

Similar Items